BioSleeve Access

The BioCompound is not built around individual ideas. It is built around a system.

Public readers see companies with a short summary as they enter the public catalogue. Paid subscribers receive the full written research layer and the ongoing analytical record.

Choose Your Access Level

Choose how you want to follow the BioCompound system: sequentially as names enter the public record, or through immediate access to the current 12-company BioSleeve library.

Sequential Access — $249/year

Receive each full deep dive as it enters the public record, plus monthly research memos and follow-up analysis.

Sequential Access includes:

• Twelve full deep dives over a twelve-month subscription, delivered as companies enter the public catalogue
• Monthly research memo scoped to publicly released names
• Sleeve reassessment notes on publicly released names
• Failure analyses on publicly released names
• Archive access to publicly released deep dives during the subscription period

Sequential Access is for readers who want to follow the framework as the public record builds.

Full Library Access — $448/year

Immediate access to the current 12-company BioSleeve library, including names not yet publicly released, plus monthly research memos and follow-up analysis.

Full Library Access includes:

• Immediate access to the current 12-company BioSleeve library
• Names before they enter the public catalogue
• Monthly research memo covering all names in the model
• Sleeve reassessment notes on all model names
• Failure analyses on all model names
• Current-cycle archive access during the subscription period

Full Library Access is for readers who want the current research library on day one.

The Standalone Alternative

Not ready for a subscription?

Publicly released companies can be purchased individually as standalone deep dives for $45. Each standalone purchase includes the full deep dive PDF, the Full Framework methodology document, and a $45 credit toward any Paid Access if upgraded within 30 days.

Official Checkout Description

Full access to The BioCompound's biotech equity research, including extended company analyses, framework-based research commentary, and ongoing analytical updates.

What Paid Access Is Not

Paid access is not a signal service, a trade log, a managed portfolio, or personalized investment advice.

The product is research. It does not tell you what to buy or when. It documents how one framework evaluates publicly traded biotech companies over time.

Need more time or review